Arbaclofen

Dr. Richard E. Frye, MD, PhD
Behavioral Child Neurologist

Clinical potential, safety, and tolerability of arbaclofen in the treatment of autism spectrum disorder

Frye RE. Clinical potential, safety, and tolerability of arbaclofen in the treatment of autism spectrum disorder. Drug Healthc Patient Saf. 2014 May 10;6:69-76. doi: 10.2147/DHPS.S39595. PMID: 24872724; PMCID: PMC4025936.

Read Article

2023-02-20T02:13:53+00:00Published Articles|

Title

PROFESSIONAL DISCLAIMER

The Site cannot and does not contain medical/health advice. The medical/health information is provided for general informational and educational purposes only and is not a substitute for professional advice. Accordingly, before taking any actions based upon such information, we encourage you to consult with the appropriate professionals. We do not provide any kind of medical/health advice. THE USE OR RELIANCE OF ANY INFORMATION CONTAINED ON THE SITE OR OUR MOBILE APPLICATION IS SOLELY AT YOUR OWN RISK.

Please read the Terms and Conditions document.

Dr. Richard E. Frye, MD, PhD Behavioral Child Neurologist

Dr. Richard E. Frye, MD, PhD Behavioral Child Neurologist

Arbaclofen

Clinical potential, safety, and tolerability of arbaclofen in the treatment of autism spectrum disorder

Title

PROFESSIONAL DISCLAIMER

Dr. Richard E. Frye, MD, PhD
Behavioral Child Neurologist

Dr. Richard E. Frye, MD, PhD
Behavioral Child Neurologist